Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants

Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RLYB116 (with an improved impurity profile) following repeated administration of RLYB116 in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
Rallybio
Treatments:
Injections